Balancing Efficacy and Safety: Managing Adverse Events With IMiDs in Multiple Myeloma
Immunomodulatory drugs (IMiDs) such as thalidomide, lenalidomide, and pomalidomide are integral to multiple myeloma (MM) treatment, improving survival and quality of life....
MS, MMSc, PA-C
Associate Chief of Education, Winship Cancer Institute of Emory University
Patient Management Guidelines
National Comprehensive Cancer Network Clinical Practice Guidelines
The National Comprehensive Cancer Network Clinical Practice Guidelines has evidence-based guidance on the diagnosis, workup, and management of multiple myeloma.
These guidelines provide recommendations on treatment for both patients who are newly diagnosed with multiple myeloma and patients who have relapsed/refractory disease, plasma cell leukemia, solitary plasmacytoma, and smoldering myeloma.
High-Fiber Plant-Based Diet Delays Progression From MGUS/SMM to Multiple Myeloma in Pilot Study
Researchers of this pilot study assessed the impact of a high-fiber plant-based dietary (HFPBD) intervention on 20 patients with monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM)....
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Advances in Diagnosing and Treating High-Risk Multiple Myeloma
High-risk multiple myeloma (MM) is a challenging condition to diagnose and treat, requiring effective tools to identify patients and deliver targeted therapies....
Evaluating MRD Detection Methods in High-Risk Smoldering Multiple Myeloma: Sensitivity and Prognosis
This study evaluated the performance of mass spectrometry (MS), serum protein electrophoresis /immunofixation electrophoresis (IFE), and next-generation flow cytometry (NGF) for detecting minimal residual disease (MRD) in patients with high-risk...
Multiparametric Flow Cytometry -Based MRD Assessment With DURAClone for Multiple Myeloma Post-ASCT
This study aimed to develop a multiparametric flow cytometry-based minimal residual disease (MRD) assessment protocol using the DURAClone method for patients with multiple myeloma (MM), particularly after autologous stem cell...
CHIP Tied to Higher CVD Risk in Patients With Multiple Myeloma Undergoing HCT
Researchers of a study investigating the role of clonal hematopoiesis of indeterminate potential (CHIP) in cardiovascular disease (CVD) among patients with multiple myeloma (MM) undergoing hematopoietic stem cell transplant (HCT)...
CURATED BY: Laura J. Zitella, MS, RN, ACNP-BC, AOCN
Revealing Multiple Myeloma Origins: Premalignant Disorders and Biomarker Advances
Preexisting plasma cell disorders, such as monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), are identified in at least one-third of patients with multiple myeloma (MM)....
